Jeffrey Wolf, MD, on Implications of Findings from Multiple Myeloma Study Presented at ASH

Video

Wolf touched on the implications of results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma.

Jeffrey Wolf, MD, of the University of California San Francisco, discussed with CancerNetwork the implications of the results from a study investigating outcomes when making clinical decisions based on the MRD status of patients with multiple myeloma presented at the 2020 American Society of Hematology (ASH) Annual Meeting.

Transcription:

So, what we discovered when we looked at those 58 people who had decisions made, and we compared it to the other patients where decisions weren’t made, we found that there were more people that achieved MRD-zero because the change allowed them to get to MRD-zero. And, for patients [where] their decision was controlled longer, that is the progression-free survival, improved significantly from 75 months to 97 months. So, we believe that by measuring MRD and using it to make decisions, you can achieve better outcomes for your patient.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content